Biotech Values

[DewDiligence]

MCUR’s CureXcell fails second phase-3 trial—now a reverse-merger candidate (IMO):

http://www.sec.gov/Archives/edgar/data/1606012/000156761915001398/s001072x1_ex1.htm

The second phase-3 was in diabetic foot ulcers; the first phase-3, which also failed, was in venous leg ulcers (#msg-116348664).

All MCUR has left is its cash—about $30M as of 9/30/15. It is now a plausible reverse-merger candidate for a private company who wants to go public via the back door.